Memorial Sloan Kettering Cancer Center
The purpose of this study is to find out whether the combination of elranatamab and cyclophosphamide is an effective treatment for people with relapsed/refractory multiple myeloma (MM) who have risk factors that may affect how well their disease would respond to elranatamab alone.
Inclusion Criteria: * Documentation of Disease: * Patients must have pathologically confirmed diagnosis of multiple myeloma (MM) as defined according to 2014 IMWG criteria. * Measurable disease defined by at least 1 of the following: * Serum M-protein ≥0.5 g/dL by SPEP * Serum immunoglobulin free light chain ≥10 mg/dL (≥100 mg/L) AND abnormal serum immunoglobulin kappa to lambda free light chain ratio (\<0.26 or \>1.65) * Urinary M-protein excretion ≥200 mg/24 hours by UPEP * Bone marrow plasma cell percentage (in aspirate or biopsy, whichever is higher) of ≥30% * Myeloma bone…
Elranatamab-bcmm is a recombinant, humanized, bispecific IgG2 kappa antibody
Cyclophosphamide is a synthetic antineoplastic drug chemically related to the nitrogen mustards